Presentation 19,20
医学関係が続きます。
Drug Deliveryに関する記述。
Presentation 19
Innovative Solutions For Transdermal Drug Delivey The RF-Microchannels Technology
Dr. Hagit Sacks
TransPharma Medical
******************************************
Authors:
Dr. Hagit Sacks, Dr. Galit Levin, Dr. Hana Gadasi, Dr. Zev Sohn, Dr. Daphna Heffetz
Session abstract:
The continuing consolidation of the pharmaceutical industry and an impending stream of major drug patent expirations are driving the escalating demand for rapid new product development. Drug-delivery technologies can provide an alternate route for drug administration thatincreases theefficacy and safety of both new and existing drugs. This is particularly important for drugs thatcannot currently be delivered easily by conventional routes or dosage forms.TransPharma's RF-MicroChannel system was developed to address the limitations of current transdermal delivery.The RF-MicroChannel technology uses radio-frequency (RF) electrical energy to create passages through the skin.
This novel and unique approach provides the following advantages over all other approaches: It enables delivery of a wide range of molecules, including proteins; RF-MicroChannels are formed rapidly and causes minimal skin trauma and discomfort; The dimensions and density of the RF-MicroChannels created can be precisely controlled, depending on the requirements of the drug; The duration of the RF-MicroChannels in the skin can last up to 24 hours or more.
This prolonged recovery time enables relatively high flux rates and provides for both constant and injection-like drug blood levels; Uniformity of RF-MicroChannels through all skin types is fully controlled by a unique feedback mechanism not offered by any other active technology; The safety and efficacy of TransPharma's technology was demonstrated in several pre-clinical and clinical studies using several drugs. RF-MicroChannel patches are likely to become the delivery devices of choice for biotech drugs in few years, when RF-MicroChannel products will begin to enter the commercial market.
****************************************
http://www.transpharma-medical.com/
http://www.drugdeliverytech.com/
http://square.umin.ac.jp/js-dds/
****************************************
Presentation 20
Cryomyolysis a Nover technology for treatment of Symptomatic Uterine Fibroids
Dr.Doris Schechter
Galil Medical
****************************************
Cryosurgery is a method of treating benign and malignant diseases by the use of tissue-freezing temperatures (-20℃ is considered to cause irreversible tissue destruction). Galil-Medical, (Yokneam, Israel) has developed an innovative cryogenic technology by which, poten cooling (down to -140℃) of an ultra-thin (17-gauge) needle's tip is produced by the expansion of compressed Argon gas after passage through a restricting orifice (Joule-Thomson effect) inside the needle. This allows very fast and controllable destruction of any tumorous tissue.
The cryogenic needles are inserted percutaneously and directed towards their target under imagine guidance with or without laparoscopic assistance. Freezing is monitored by real-time ultrasound imaging of the iceball propagation and by continuous tissue temperature measurements. Galil-Medical's FDA-approved technology is currently worldwide successfully applied for treatment of various malignant and benign conditions, such as: prostate, renal, liver, soft-tissue tumors, breast fibroadenomas, as well as cryoanalgesia and others.
Recently we studied the effectiveness of cryosurgery in the treatment of 20 premenopausal women with symptomatic fibroids who completed child bearing. At 3 month follow-up median fibroid shrinkage was 58% and symptoms were significantly relieved in 19 patients. Further follow-up is on-going and post market studies in Europe are underway. Uterine fibroids are one of the most common benign gynecological conditions experienced women. About 25-30% of premenopausal women develop significant quality of life impair symptoms requiring medical intervention.
The most commonly applied method for treating symptomatic fibroids in women who completed their family planning is hysterectomy, with over 230,000 hysterectomies per year in the US related to symptomatic fibroids. An increasing demand for minimally invasive uterus preserving treatments even in women, who do not wish to maintain fertility, opened a business opportunity for Galil Medical's technology in the gynecology arena.
*****************************************
http://www.galilmedical.com/
Cryosurgery 低温外科手術
Symptomatic treatment 対症療法
原因療法と対症療法
アルゴンガス
FDA
